Vtv Therapeutics Inc. (VTVT) Stock Price & Analysis
Vtv Therapeutics Inc. (VTVT) fell 0.90% to USD 31.77 as of June 10, 2026 at 01:03 UTC, according to Nexqual real-time market data.
VTVT last closed at USD 32.06; the session ranged USD 31.4–32.61 on volume of 12,651 shares. Market capitalization is $125.13M, with a 52-week range of USD 14–44 (NCM). Source: Nexqual, June 10, 2026 at 01:03 UTC.
Key Statistics (as of June 10, 2026 at 01:03 UTC)
| Price | USD 31.77 |
|---|---|
| Change | ▼ 0.90% (down) |
| Previous Close | USD 32.06 |
| Open | USD 32.61 |
| Day Range | USD 31.4 – 32.61 |
| 52-Week Range | USD 14 – 44 |
| Volume | 12,651 shares |
| Market Cap | $125.13M |
| Exchange | NCM |
Technical Analysis (VTVT)
Nexqual's technical model rates VTVT "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 01:03 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 37.99 (neutral) |
| vs SMA50 | Below (USD 34.92) |
| MACD | -0.55 (negative) |
Analyst Ratings (VTVT)
Wall Street analysts rate VTVT "None" based on 6 analysts, with a mean price target of USD 53 (range USD 44–67), per Nexqual as of June 10, 2026 at 01:03 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 53 |
| High Target | USD 67 |
| Low Target | USD 44 |
| Buy / Hold / Sell | 6 / 0 / 0 |
Earnings (VTVT)
| EPS Estimate | USD -0.99 |
|---|---|
| Revenue Estimate | $150,000 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 1.65 vs est 0.21 ▲ beat |
| 2025-12-31 | USD -0.58 vs est -1.09 ▲ beat |
| 2025-09-30 | USD -1.08 vs est -0.98 ▼ miss |
| 2025-06-30 | USD -0.92 vs est -0.83 ▼ miss |
Source: Nexqual, June 10, 2026 at 01:03 UTC.
Financials & Fundamentals (VTVT)
| Total Revenue | $36.84M |
|---|---|
| Gross Margin | +34.83% |
| Operating Margin | +63.15% |
| Profit Margin | +6.11% |
| ROE | -1.47% |
| Current Ratio | 14.36 |
| Total Cash | $98.09M |
| Total Debt | $0 |
| Free Cash Flow | $5.28M |
Source: Nexqual, June 10, 2026 at 01:03 UTC.
Financial Health Score (VTVT)
Nexqual rates Vtv Therapeutics Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 01:03 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $98M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$10M |
| Efficiency | Critical — ROE -1%, ROA -2.9% |
Ownership (VTVT)
| Insider Ownership | +38.98% |
|---|---|
| Institutional Ownership | +38.35% |
| Shares Outstanding | 3.94M |
| Float | 2.14M |
| Short % of Float | +6.60% |
Source: Nexqual, June 10, 2026 at 01:03 UTC.
Leadership (VTVT)
Vtv Therapeutics Inc. is led by Paul J. Sekhri (age 67), CEO, President & Chairman of the Board, per Nexqual as of June 10, 2026 at 01:03 UTC.
| CEO, President & Chairman of the Board | Paul J. Sekhri (age 67) |
|---|---|
| Executive VP & CFO | Michael Steven Tung (age 51) |
| Chief Scientific Officer & Executive VP | Carmen Valcarce |
| Executive VP of Corporate Development & Director | Richard S. Nelson (age 55) |
Major Backers & Investors (VTVT)
Notable institutional backers of Vtv Therapeutics Inc. include Samsara BioCapital, LLC, Fidelity, FMR, LLC, according to Nexqual as of June 10, 2026 at 01:03 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Samsara BioCapital, LLC | 7.58% |
| Fidelity | 7.28% |
| FMR, LLC | 6.61% |
| Millennium Management | 5.24% |
| Siren, L.L.C. | 4.14% |
| Baker Bros. Advisors, LP | 3.77% |
| Trails Edge Capital Partners, LP | 3.54% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 5.91% |
| Geode Capital | 0.83% |
| Northern Trust | 0.46% |
Source: Nexqual, June 10, 2026 at 01:03 UTC.
From Vtv Therapeutics Inc.'s Latest SEC 10-K Filing (filed 2026-03-10)
Key Strengths & Strategy (as disclosed to the SEC)
- vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases.
- Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes.
- The company is also investing a range of molecules across various indications for chronic diseases.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| XBIO | Xenetic Biosciences, Inc. | USD 3.08 | ▼ 0.23% |
| OGEN | Oragenics Inc. | USD 0.6 | ▲ 1.69% |
| TENX | Tenax Therapeutics, Inc. | USD 10.73 | ▲ 0% |
| DARE | Dare Bioscience, Inc. | USD 1.92 | ▲ 2.13% |
| PRPO | Precipio, Inc. | USD 23.32 | ▼ 0.72% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 01:03 UTC. This page is informational and not investment advice.